Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
Takhzyro
Pharma
Takeda expects patent expirations to weigh on earnings
As several of Takeda’s top drugs veer toward the patent cliff, the Japanese drugmaker is buckling up for a bumpy ride.
Fraiser Kansteiner
May 12, 2023 11:10am
New HAE drugs from Takeda, BioCryst are gaining popularity
Mar 18, 2022 11:16am
Samsung, Moderna, Brii and more—Fierce Pharma Asia
Aug 27, 2021 9:20am
ICER is urging steep discounts on Takeda and CSL drugs
Aug 24, 2021 2:18pm
FDA delays Takeda's Eohilia as EMA extends dengue vaccine review
Jul 30, 2021 10:50am
Sinopharm, Sinovac, Astellas, BGI and more—Fierce Pharma Asia
Jul 16, 2021 8:50am
